SOCE might be a good way to treat metastatic RCC, a type of cancer that doesn’t respond to common treatments like anti-VEGF inhibitors and anti-mammalian targets of rapamycin (mTOR) blockers, for reasons that are either genetic or acquired. This evidence concerns the gene MTOR and renal cell adenocarcinoma.